Moderna Stock Price, News & Analysis

Moderna (NASDAQ: MRNA) has announced its upcoming participation in two major investor conferences in June 2025. The company will present at the Jefferies Global Health Care Conference on June 5th at 10:30am ET and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11th at 8:40am ET.

Live webcasts of both presentations will be accessible through the "Events and Presentations" section on Moderna's investor website. Replays will remain available for at least 30 days after each presentation.

Moderna (NASDAQ:MRNA) has submitted an FDA application for its updated Spikevax 2025-2026 formula, specifically designed to target the SARS-CoV-2 LP.8.1 variant. The submission aligns with FDA guidance recommending COVID-19 vaccines be updated to a monovalent JN.1 lineage, with preference for the LP.8.1 variant.

Moderna (NASDAQ:MRNA) has voluntarily withdrawn its Biologics License Application (BLA) for mRNA-1083, its combination flu/COVID vaccine candidate for adults aged 50 and older. The withdrawal comes after consultation with the FDA. The company plans to resubmit the BLA later in 2025 after obtaining vaccine efficacy data from the ongoing Phase 3 trial of mRNA-1010, its investigational seasonal influenza vaccine. Interim data from the mRNA-1010 trial is expected to be available in summer 2025.

Cellarity has appointed Ted Myles as its new Chief Executive Officer and CEO-Partner at Flagship Pioneering. Myles brings extensive biopharma leadership experience, previously serving as CFO and COO of Scholar Rock where he raised over $1 billion and led the company through a successful Phase 3 study. His prior roles include executive positions at AMAG Pharmaceuticals, Ocata Therapeutics, and PrimeraDx.

The appointment comes as Cellarity prepares for its first clinical study in 2025. The company leverages an AI/ML-enabled platform for drug discovery, focusing on understanding dysregulated pathways in diseased human cells. Their lead program, CLY-124, is a potential first-in-class small molecule for sickle cell disease treatment, targeting fetal hemoglobin induction through a novel mechanism, with clinical development expected to begin in mid-2025.

Moderna (NASDAQ: MRNA) has announced its upcoming participation in Bernstein's 41st Annual Strategic Decisions Conference (SDC). The presentation is scheduled for Thursday, May 29th, 2025, at 10:00 AM ET. Investors and interested parties can access a live webcast of the presentation through the "Events and Presentations" section on Moderna's investor website at investors.modernatx.com. The webcast recording will remain available on the company's website for a minimum of 30 days after the presentation.

Flagship Pioneering and Quotient Therapeutics have appointed Rahul Kakkar, M.D. as CEO-Partner and Chief Executive Officer. Dr. Kakkar brings nearly 20 years of experience in biotech entrepreneurship and medicine, previously serving as CEO of Tome Biosciences and Pandion Therapeutics, which was acquired by Merck for $1.85 billion.

Jake Rubens, Quotient's co-founder and former CEO, will transition to a board director role after successfully establishing the company's first industrial platform for discovering drug targets through somatic genomics and securing a collaboration with Pfizer in cardiovascular and renal diseases.

Dr. Kakkar, who continues to practice at Brigham and Women's Hospital and lecture at Harvard Medical School, will lead Quotient's efforts in advancing its pipeline and platform technology. The company's focus on somatic genomics aims to discover novel drug targets and create first-in-class medicines for various diseases.

Etiome, unveiled by Flagship Pioneering with a $50 million initial commitment, introduces its Temporal Biodynamics™ AI-powered platform for preemptive healthcare. The platform represents the first end-to-end solution to detect and preempt disease progression before it becomes critical.

The technology characterizes disease progression over time by combining multimodal population-level data and single cell omics with artificial intelligence. It identifies Biostage Markers - stage-specific biomarkers indicating patient disease progression - and develops targeted Biostaged Medicines.

Initially focusing on metabolic, neurodegenerative, pre-cancerous, and autoimmune diseases, Etiome aims to reduce morbidity, lower healthcare costs, and extend healthy lifespans. The company emerges after four years of platform development under Flagship Pioneering's Preemptive Health and Medicine Initiative.

Moderna (NASDAQ:MRNA) has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025. The company will host a live conference call and webcast at 8:00 a.m. ET to present the results and provide a corporate update.

Investors can access the live webcast through the 'Events and Presentations' section on Moderna's investor website. The archived version will be available approximately two hours after the conference call and remain accessible for one year.